Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Hot Line Presentation of Primary Results from ACACIA-HCM to Elaborate on Positive Topline Results in Patients with Non-Obstructive Hypertrophic Cardiomyopathy

Company to Host In-Person and Virtual Investor Event to Discuss Results from Late-Breaking Science Presentations

SOUTH SAN FRANCISCO, Calif., July 07, 2026 — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced three Late Breaking Science abstracts were accepted for presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany, including a Hot Line presentation of the primary results from ACACIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (HCM).

Hot Line and Late-Breaking Science Presentations

Title: ACACIA-HCM: Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy Presenter: Ahmad Masri, M.D., M.S., Associate Professor of Medicine, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University Date: Friday, August 28, 2026 Session Title: Hot Line 1 Session Time: 11:00 AM – 12:15 PM CEST Presentation Time: 11:45 – 11:55 AM CEST Location: Munich, Main Auditorium (Hall B3)

Title: Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy - Results from the ACACIA-HCM Trial Presenter: Sheila Hegde, M.D., MPH, Assistant Professor, University of Texas Southwestern Medical Center – Dallas, TX and Affiliate Faculty, Brigham and Women’s Hospital, Boston, MA Date: Saturday, August 29, 2026 Session Title: Late-Breaking Clinical Science: Hypertrophic Cardiomyopathy Session Time: 4:15 – 5:15 PM CEST Presentation Time: 4:15 – 4:30 PM CEST Location: Achgabat (Hall A3)

Title: Aficamten vs. Metoprolol Monotherapy in Obstructive Hypertrophic Cardiomyopathy According to Pre-Trial Treatment in MAPLE-HCM Presenter: Fernando Dominguez, M.D., Ph.D., Consultant Cardiologist, Hospital Universitario Puerta De Hierro Majadahonda – Madrid, Spain Date: Saturday, August 29, 2026 Session Title: Late-Breaking Clinical Science: Hypertrophic Cardiomyopathy Session Time: 4:15 – 5:15 PM CEST Presentation Time: 4:30 – 4:45 PM CEST Location: Achgabat (Hall A3)

Investor Event and Webcast

Cytokinetics will host an in-person and virtual investor event onsite at ESC to discuss results from the Late-Breaking Science presentations at the Congress. Additional details including the date, time and registration information will be announced at a later date.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to discuss the results with the U.S. FDA and other regulatory authorities. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.